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Abstract 
Background: Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recom-
mended for preventing malaria in pregnancy in areas of moderate-to-high transmission in sub-Saharan Africa. How-
ever, due to increasing parasite resistance to SP, research on alternative strategies is a priority. The study assessed the 
implementation feasibility of intermittent screening and treatment (ISTp) in the second and third trimester at ante-
natal care (ANC) with malaria rapid diagnostic tests (RDTs) and treatment of positive cases with dihydroartemisinin-
piperaquine (DP) compared to IPTp-SP in western Kenya.
Methods: A 10-month implementation study was conducted in 12 government health facilities in four sub-counties. 
Six health facilities were assigned to either ISTp-DP or IPTp-SP. Evaluation comprised of facility audits, ANC observa-
tions, and exit interviews. Intermediate and cumulative effectiveness analyses were performed on all processes 
involved in delivery of ISTp-DP including RDT proficiency and IPTp-SP ± directly observed therapy (DOT, standard of 
care). Logistic regression was used to identify predictors of receiving each intervention.
Results: A total of 388 and 389 women were recruited in the ISTp-DP and IPTp-SP arms, respectively. For ISTp-DP, 90% 
(289/320) of eligible women received an RDT. Of 11% (32/289) who tested positive, 71% received the correct dose 
of DP and 31% the first dose by DOT, and only 6% were counselled on subsequent doses. Women making a sick visit 
and being tested in a facility with a resident microscopist were more likely to receive ISTp-DP (AOR 1.78, 95% CI 1.31, 
2.41; and AOR 3.75, 95% CI 1.31, 2.40, respectively). For IPTp-SP, only 57% received a dose of SP by DOT. Payment for a 
laboratory test was independently associated with receipt of SP by DOT (AOR 6.43, 95% CI 2.07, 19.98).
Conclusions: The findings indicate that the systems effectiveness of ANC clinics to deliver ISTp-DP under routine 
conditions was poor in comparison to IPTp-SP. Several challenges to integration of ISTp with ANC were identified that 
may need to be considered by countries that have introduced screening at first ANC visit and, potentially, for future 
adoption of ISTp with more sensitive RDTs. Understanding the effectiveness of ISTp-DP will require additional research 
on pregnant women’s adherence to ACT.
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Background
Malaria remains a major cause of preventable adverse 
maternal health and birth outcomes [1, 2]. Each year an 
estimated > 30 million pregnancies in sub-Saharan Africa 
are exposed to malaria [3]. Prevention of malaria among 
pregnant women in this region relies on intermittent 
preventive treatment with sulfadoxine-pyrimethamine 
(IPTp-SP) and use of long-lasting insecticide-treated nets 
[4], however the effectiveness of these strategies is threat-
ened by the development of SP resistance in parasites [5, 
6] and insecticide resistance in the vectors [7].
Research efforts to find alternative chemoprevention 
strategies for the Africa region have intensified over 
recent years, with mixed results [8]. Six trials to evaluate 
alternative drugs to replace SP for IPTp showed that amo-
diaquine [9] and mefloquine [10, 11], were not suitable 
due to poor tolerability and chloroquine-azithromycin 
was less efficacious than SP [12]. Four trials explored an 
alternative prevention strategy of intermittent screening 
and treatment (ISTp) at every scheduled antenatal care 
(ANC) visit with malaria diagnosis using a rapid diag-
nostic test (RDT) and treatment of positive cases with an 
artemisinin-based combination therapy (ACT) [13–16]. 
The trials concluded that ISTp with the current genera-
tion of malaria RDTs was not a suitable alternative strat-
egy to IPTp-SP, and several trials with new more sensitive 
RDTs are currently ongoing (ter Kuile, pers. commun.). 
In addition, four new trials to assess the efficacy, safety 
and tolerability of dihydroartemsinin-piperaquine (DP) 
for IPTp are either ongoing (IMPROVE NCT03208179, 
IMPROVE-2 NCT04158713, NCT02793622) or have 
been published [17] following promising results from two 
earlier exploratory trials of IPTp with DP in Kenya and 
Uganda [15, 18].
The acceptability of both ISTp-DP and IPTp-DP has 
been assessed in the context of some of these clinical 
trials [19–23], however the systems effectiveness and 
uptake of potential alternatives can only authentically be 
assessed under real life conditions. Replacement of a sin-
gle dose of IPTp-SP at each ANC visit with more complex 
and expensive strategies involving multi-day ACT regi-
mens, such as ISTp-DP or IPTp-DP, will be a major deter-
minant of uptake of these interventions once embedded 
in a national malaria control programme and ultimately 
their public health impact. However, little is known about 
their implementation feasibility in this setting.
The study aimed to assess the implementation feasibil-
ity of ISTp-DP compared to IPTp-SP in a routine health 
system setting in western Kenya, conducted in a sub-
county adjacent to the site of an open-label three-arm 
randomized controlled superiority trial comparing IPTp 
or ISTp with DP to IPTp-SP [15]. This was a mixed meth-
ods study and the results of the quantitative component 
are reported here; the qualitative results are published in 
a companion paper (Hoyt, pers. commun.).
Methods
Study sites and study design
The study was conducted in 12 health facilities in four 
administrative units (subcounties) in Kisumu County 
in western Kenya: Muhoroni, Nyakach, Kisumu West 
and Seme. The study had two phases, an implementa-
tion phase which ran for ten months between September 
2014 and June 2015, and an evaluation initiated mid-
way from February to June 2015. The overall aims of this 
mixed methods study were to assess implementation fea-
sibility using the framework constructs of Bowen et  al. 
[24]: (1) acceptability, (2) demand, (3) implementation, 
(4) practicality, (5) integration, (6) adaptation and (7) 
expansion. The constructs of acceptability and demand 
are addressed in the qualitative study (Hoyt, pers. com-
mun.), while implementation, practicality and integration 
are addressed directly by both quantitative and qualita-
tive studies (Additional file 1: Table S1). The quantitative 
study addresses implementation through systems effec-
tiveness analyses including both the overall implemen-
tation of each of the interventions, and each component 
of the interventions. Integration is addressed through 
exploration of the provision of RDT testing and provi-
sion of DP (to RDT test positive cases) by nurses in ANC, 
whereas in routine practice RDTs are performed by labo-
ratory staff in laboratories, and artemisinin-based combi-
nation therapy for treatment of malaria given by clinical 
doctors. Other constructs are indirectly addressed in the 
quantitative study including practicality and adaptation 
and further explored in the qualitative study.
Methods used in the quantitative evaluation reported 
here comprised health facility audits, observations in 
ANC clinics, and exit interviews with pregnant women 
leaving ANC clinics. Health facilities were purposefully 
selected based on the feasibility of achieving the required 
sample size within a 3-month period using available ANC 
records. Three county or subcounty hospitals (level 4 
facilities) and three health centres (level 3 facilities) were 
included in each study arm. The health facilities were first 
split into two similar groups using health management 
Keywords: Intermittent screening and treatment, Intermittent preventive treatment, Dihydroartemisinin-
piperaquine, Health system delivery, Pregnant women, Health providers, Kenya
Page 3 of 16Hill et al. Malar J          (2020) 19:433  
information systems (HMIS) data on factors likely to 
have an effect on study outcomes: (1) ratio of ANC regis-
trants per professional staff in ANC, and (2) coverage of 
one and two doses of IPTp-SP in the previous 12 months. 
Six matched health facilities were then assigned to one of 
two arms, ISTp-DP (i.e. the intervention arm) or the cur-
rent IPTp-SP policy (i.e. the control arm).
The implementation phase began with sensitization 
and training of Ministry of Health (MOH) staff in the 
study sites. Members of the County Health Management 
Team were first sensitized and provided with an overview 
of the study design. Health facility staff involved in deliv-
ering ANC services, including nurses, clinical officers, 
laboratory staff, data clerks, and pharmacists, were then 
trained at a central location in each subcounty between 
August and September 2014. Health staff received a 
refresher course on Kenyan malaria in pregnancy and 
related policies, including IPTp-SP, and staff in the ISTp-
DP arm received additional training on the use of RDTs, 
quality control of drugs and RDTs, stock control and 
storage of RDTs and administration of DP. On comple-
tion of training, health staff in the ISTp-DP facilities were 
provided with standard operating procedures (SOPs) on 
managing malaria cases, performing RDTs, and adminis-
tration of DP. DP was supplied to the facilities in the ISTp 
arm for the duration of the study, and buffer supplies 
of SP and RDTs of the same brands used by the MOH 
[namely histidine–rich protein-2 (HRP-2)/Plasmodium 
lactate dehydrogenase (pLDH) combination RDTs (First 
Response® Malaria pLDH/HRP2 Combo Test, Premier 
Medical Corporation Ltd, India)] provided in the event 
of stockouts in routine MOH supplies. Health facility 
stocks of anti-malarial drugs (DP and SP) and RDT kits 
were monitored and replenished when needed to avoid 
stock-outs, however gloves were not provided. The sup-
ply chain, therefore, does not reflect operational realities 
however other external interference with the study health 
facilities by study staff such as additional guidance or 
supervision was kept to a minimum. Respective County 
and subcounty Health Management Teams were encour-
aged to continue routine supervision of health facilities 
and ANC services throughout the study.
Pregnant women attending study health facilities 
for scheduled focused ANC visits during their second 
and third trimester received the standard ANC pack-
age of care, and either IPTp-SP or ISTp-DP depending 
on study arm. Pregnant women attending ANC in the 
IPTp-SP arm received three tablets of quality-assured SP 
(supplied by Durbin PLC, Middlesex, UK, 500  mg sulf-
adoxine/25 mg pyrimethamine /tablet) and those in the 
IPTp-DP arm received a standard 3-day course with DP 
(Eurartesim®, Sigma Tau, Pomezia, Italy, 40  mg dihy-
droartemisinin /320  mg piperaquine /tablet). According 
to national policy [25], women receiving IPTp-SP 
receive a single dose of three tablets of SP under directly 
observed therapy (DOT). Women infected with HIV on 
daily cotrimoxazole are not given IPTp-SP. Since 2010, all 
health facilities switched to low dose folic acid, with the 
recommendation for any high dose folic acid to be taken 
14 days after a dose of SP [MOH, unpublished]. Women 
in the ISTp-DP arm who tested RDT positive were pre-
scribed DP based on body weight (24 to 35.9 kg—2 tab-
lets; 36 to 74.9 kg—3 tablets; > 75 kg—4 tablets). Health 
staff were trained to administer the first dose of DP under 
DOT and provide the remaining two doses and instruc-
tions for how to take them at home. Women with a 
known HIV positive status were not tested with an RDT 
unless they were symptomatic for malaria, and if test-
positive they were treated following national guidelines 
for malaria treatment during pregnancy.
Evaluation procedures
Primary endpoints and sample size
The primary endpoint was the “the proportion of eli-
gible women receiving a correctly administered dose of 
SP, with the 1st dose given by DOT” in the IPTp-SP arm, 
and the “proportion of eligible pregnant women screened 
with an RDT and treated according to guidelines” in the 
ISTp-DP arm. A total of 776 ANC attendees making any 
visit in second and third trimesters were enrolled for the 
structured observations and exit interviews, (388 for 
each intervention). This was a conservative sample size 
that allowed 10% precision in the outcome estimate with 
a frequency of 50%, with 95% confidence and a design 
effect of 2.
Prior to conducting observations and exit interviews 
at a health facility information about available resources 
(staffing, services, equipment and stock) and their staff 
(post, cadre, qualifications, training, access to guidelines) 
was collected, and other factors which may be associ-
ated with uptake of the interventions by pregnant women 
assessed.
Data collection
Prior to the data collection, informed consent was sought 
from the in-charge of each health facility and key staff 
working in ANC. During health worker enrollment, 
information was obtained on professional background, 
years in post, any recent training and access to malaria 
guidelines. Pregnant women attending routine ANC 
were consented once they completed ANC registration 
and enrolled women were followed throughout their 
ANC visit by a field worker, from registration until exit 
from the health facility. Field workers used a structured 
checklist to assess health provider adherence to study 
SOPs for prescribing and dispensing practices (SP, DP), 
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proficiency in performing RDTs (ISTp), and adherence 
to national policy for other routine ANC services. Com-
pletion of the checklist was accompanied by collection of 
unstructured comments on the process to provide con-
text to the findings of structured observations. Exit inter-
views were then conducted with each consenting woman 
on completion of the ANC visit. Pregnant women were 
approached to participate and consented at ANC regis-
tration. The selection of pregnant women was based on 
the availability of field workers, that is, non-probability 
sampling. On completion of an exit interview, the field 
worker returned to the registration desk and repeated 
the process with the next pregnant woman in the queue. 
Exit interviews included questions on the women’s visit 
(symptoms or reason for visit, pregnancy history, exami-
nations, tests, drugs given and understanding of how to 
take them), costs of services received at ANC and any 
previous hospitalization, and household assets.
Data analysis
Data were double entered using Epi info. All analyses 
were adjusted for survey design and clustering of health 
facilities using STATA 12.1 (StataCorp). Two systems 
effectiveness analyses were performed for each study 
intervention and for RDT testing proficiency: (1) cumu-
lative effectiveness and (2) intermediate effectiveness of 
each process in the delivery chain. For IPTp, intermediate 
processes assessed comprised: (1) 2nd or 3rd trimester 
visit; (2) given any SP; (3) given 3 tablets of SP; (4) given 
SP by DOT; or where was not given IPTp-SP by DOT (5) 
left the facility with 3 tablets of SP and (6) knows how 
they would be taken; and (7) a composite endpoint com-
bining 4) and 6). IST intermediate processes were: (1) 
2nd or 3rd trimester visit; (2) given an RDT test; (3) RDT 
negative and not given an anti-malarial; (4) RDT positive 
and given any DP; (5) given correct dose of DP; (6) given 
first dose of DP by DOT; (7) Correct number of tablets 
given; (8) Health worker describes how to take remaining 
doses; (9) Woman able to repeat instructions; and (10) a 
composite endpoint combining (3) and (9) [26]. Analyses 
were restricted to women attending ANC in the second 
and third trimester, and eligible for either intervention. 
Analysis was limited to asymptomatic HIV-uninfected 
participants determined as those who did not receive any 
antiretroviral during that visit, participants who did not 
receive any anti-malarials for treatment and for whom 
information on drugs prescribed during the visit was 
available on exit. RDT testing proficiency analysis was 
assessed for 16 steps laid out in the study SOP (listed in 
Table 6). Univariate analyses were conducted of potential 
predictors of receipt of: (i) IPTp-SP by DOT vs no DOT; 
and (ii) ISTp-DP full vs incomplete regimen. Logistic 
regression models adjusted for the survey design were 
used, and adjusted Wald tests were applied to test for 
associations between predictors and outcomes. Poten-
tial predictors significant at the 10% level (p ≤ 0.1) in the 
univariate analyses were included in multivariate logistic 
models to determine which factors were associated with 
the outcomes after accounting for other potential predic-
tors, and predictors were considered significant at < 0.05 
in the final model [26]. A list of potential predictors 
and the corresponding data source are summarized in 
Table S2. Principle components analysis (PCA) was used 
to construct a wealth index in order to assess the effect of 
socio-economic status (SES) [27].
Ethics statement
The study was approved by the ethics committees of the 
Kenya Medical Research Institute’s (KEMRI) Scientific 
and Ethics Review Unit, Kenya; the Liverpool School 
of Tropical Medicine, UK; and the London School of 
Hygiene and Tropical Medicine, UK; the US Centers for 
Disease Control and Prevention, Atlanta, Georgia, USA 
relied on KEMRI. Health workers gave signed informed 
consent for structured questionnaires and for observa-
tions. Pregnant women gave signed informed consent for 
observations and exit interviews at ANC registration. In 
Kenya, pregnant women aged 15–17  years are consid-
ered emancipated minors and were consented directly. 
Permission from the County Health Management Teams 
and health facility in-charges was sought prior to initiat-
ing the study.
Results
Health facility characteristics
Using health management information systems (HMIS) 
data from 2014, health facilities in each study arm were 
reasonably well matched with respect to: total catch-
ment population (94,112 and 88,679) and number of 
ANC visits (2938 and 2454) in the IPTp and ISTp arms, 
respectively. Health facilities in the ISTp arm had higher 
numbers of ANC staff (42 versus 21 staff); no data were 
reported for facility #3 (Table  1). The catchment popu-
lation for county hospitals ranged from approximately 
21,000–23,000, for subcounty hospitals from approxi-
mately 10,000–18,000, and health centres from approxi-
mately 9000–21,000. Client to staff ratios ranged from 46 
to 543, with both extremes found at health centre level. 
All health facilities had functioning microscopes and all 
but one health centre had a resident microscopist. All 
health facilities in the ISTp arm reported using RDTs 
for malaria diagnosis in the 6 months before the survey 
with one reporting routine facility stockout of RDTs on 
the day of the facility audit which was replenished by the 
study team. One health facility in the ISTp arm reported 
a stockout of study DP in the 6 months before the survey.
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Health provider characteristics
A total of 112 health providers were interviewed; the 
mean age was 37  years and 68% were female (Table  2). 
Approximately one fifth lived in the local catchment 
area of the health facility where they worked (19%) and 
approximately one quarter were from the same sub-
county as the health facility (28%). Approximately one 
third of health providers interviewed were registered 
nurses (35%), 13% were laboratory technicians, 10% 
were trained HIV counsellors and 8% were clinical offic-
ers. Years worked in the health facility ranged from 1 
to 5 years (mean 3 years). Only some staff had received 
training relating to malaria in pregnancy either at a work-
shop or from a colleague within the last five years, rang-
ing from 20–100% for malaria in pregnancy, 30–94% for 
case management, 27–50% for RDTs (94% of laboratory 
staff and 27% of nurses) and 18–78% for ISTp. In general, 
nurses had greater access to job aids and guidelines than 
laboratory staff.
Pregnant women characteristics
A total of 777 pregnant women were observed during 
an ANC visit on the day of the survey and interviewed 
as they exited the health facility, 389 in the IPTp arm 
and 388 in the ISTp arm (Table 3). There were approxi-
mately equal numbers of women in the second and 
third trimester in both arms: 51% and 49%, respec-
tively, in the IPTp arm (mean gestation 6.4  months), 
and 49% and 51%, respectively, in the ISTp arm (mean 
gestation 6.5 months). Similarly, there was an approxi-
mately equal distribution of women attending for their 
first, second, third, fourth or more (4+) ANC visit in 
both arms, with slightly more women attending for 
their first visit in the IPTp arm (29%) and for their 
second visit in the ISTp arm (27%) compared to the 
other visits (not statistically significant). Over 40% of 
women in each arm were multigravidae aged between 
20 to 24  years. Most women were married, 78% and 
82% in the IPTp and ISTp arms respectively, and of 
Luo ethnicity, 88% and 89%, respectively. Most women 
had primary level education (55% and 53%, respec-
tively), and approximately one fifth had no education 
(30% and 24%, respectively). Over 70% of women had 
at least one child aged under 5 years, and 11–12% had 
had a child who died.
Systems effectiveness of ANC to deliver IPTp-SP
Of 336 women included in the analysis, 75% (239/319) 
received a dose of SP and all received the correct num-
ber of tablets, i.e. 3 tablets, however, only 76% (179/237) 
of these received the dose by DOT (Table 4). This trans-
lates into a cumulative effectiveness for receiving IPTp-
SP by DOT of 57%. The cumulative effectiveness for the 
composite endpoint (doses given with or without DOT) 
was 53.6%.
Systems effectiveness of ANC to deliver ISTp-DP
Of 347 women included in the analysis, 90% (289/320) 
were tested with a malaria RDT of whom 11% (32/289) 
tested positive (Table 5). Of women who tested positive, 
91% (29/32) were given DP of whom 86% (25/29) were 
given the correct dose based on the woman’s weight, 
with a cumulative effectiveness of 71%. Of the women 
receiving the correct dose, only 44% (11/25) received 
the initial dose of DP by DOT and only 18% (2/11) of 
these received instructions from the health provider 
on how to take the remaining doses. Neither of these 
women were able to repeat these dosing instructions 
on exit resulting in 0% cumulative effectiveness for 
women who tested positive. The overall cumulative 
effectiveness for the composite endpoint was 60.8%. 
The proportion of women screened with an RDT was 
relatively consistent across visit number (1–4+ visits), 
with slightly fewer women screened with an RDT at 
a first visit as these women have blood slides taken as 
part of ANC profile testing (20% [11.4, 33.9]) compared 
to 4+ visits (27% [17.7, 38.1]). More women attending 
their first ANC visit tested positive for malaria (4% [1.2, 
9.6]) than women attending for 4+ visits (2% [0.5, 5.9]) 
(not significant).
RDT proficiency among ANC and laboratory staff
Of the 289 women screened with an RDT in the ISTp 
arm, a higher proportion of tests were performed in 
ANC (95%, 274/289) than in the lab (Table 6). Cumula-
tive effectiveness for adherence to each RDT proficiency 
step in ANC was 12% (35/289) if step #5, selecting the 
fourth finger to prick for blood (65%, 82/126), and step 
#7, labelling the RDT with the patient’s name (only 
22%, 26/117 were labelled), are omitted. The omission 
of these two steps is based on the assumptions that: i) 
the finger used to collect blood does not affect the test 
result; ii) in this setting the woman is given the result 
during the consultation by the nurse during her ANC 
visit thereby removing the need to label the RDT. Two 
further steps with low adherence to the SOP in ANC 
were the wearing of gloves (47%, 129/274), which is 
important for health worker safety, and waiting time 
for the test result (30%, 35/117), which may affect accu-
racy of test results. Cumulative effectiveness for steps 
1–15 of tests performed in the lab was higher than in 
ANC (36% vs 12% without steps 5 and 7, respectively), 
the steps with lowest adherence being wearing gloves 
(73%, 11/15), selecting the fourth finger (36%, 4/11), 
and waiting time for the test result (55%, 6/11). Steps 
where ANC nurses performed better than lab staff were 
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selecting the fourth finger (percentage score difference 
of+ 29) and using guidelines (+ 11).
Predictors of women receiving IPTp-SP by DOT
Predictors of women receiving SP by DOT in the uni-
variate analysis were marital status, sick visit (as reported 
by or agreed with the woman), paid for a lab test, and 
being given drugs at the pharmacy (Table 7). In the final 
Table 3 Characteristics of pregnant women in ANC observations and exit interviews
a 11 missing; ± 5 missing
Socio-demographic data IPTp-SP (N = 389) ISTp-DP (N = 388)
n % (95% CI) n %(95% CI)
Trimestera
 2nd trimester 195 50.9 (40.6, 61.2) 188 49.2 (45.1, 53.3)
 3rd trimester 188 49.1 (38.8, 59.4) 194 50.8 (46.7, 54.9)
 Mean months gestation 6.4 (IQR 5–8) 6.5 (IQR 5–8)
ANC visit no
 1 113 29.1 (22.2, 37.0) 97 25.0 (19.3, 31.8)
 2 92 23.7 (18.4, 29.9) 104 26.8 (22.1, 32.1)
 3 97 24.9 (21.1, 29.2) 90 23.2 (16.7, 31.3)
 4+ 87 22.4 (18.4, 26.9) 97 25.0 (17.6, 34.2)
Malaria symptoms/fever
 Yes 6 6.6 (4.03, 10.61) 5 7.0 (1.90, 22.85)
 No 85 93.4 (89.39, 95.97) 66 93.0 (77.15, 98.10)
Gravidity
 Primigravidae 98 25.2 (20.36,30.73) 112 28.9 (23.95, 34.33)
 Secundigravidae 110 28.3 (25.93,30.75) 102 26.3 (20.59, 32.92)
 Multigravidae 181 46.5 (41.58,51.55) 174 44.9 (42.02, 47.71)
 Median number of births 1.62 (1.57,1.68) 1.6 (1.57, 1.69)
Age group (15–49)
 15 to 19 years 70 18.0 (14.55, 22.05) 71 18.3 (13.79, 23.87)
 20 to 24 years 163 41.9 (38.36, 45.53) 163 42.0 (36.32, 47.92)
 25 to 29 years 92 23.7 (19.18, 28.79) 92 23.7 (20.35, 27.44)
 30+ years 64 16.5 (13.33, 20.14) 62 16.0 (11.44, 21.88)
Median age 23 IQR 20–28 23 IQR 20–27
Marital status
 Married 310 79.7 (74.59, 83.99) 319 82.2 (77.07, 86.41)
 Divorced/widowed 61 15.7 (10.92, 22.00) 65 16.8 (12.69, 21.79)
 Single 18 4.6 (2.76, 7.67) 4 1.0 (0.36, 2.94)
Education level ± 
 None/nursery 115 29.8 (22.50, 38.28) 91 23.58 (19.83, 27.78)
 Primary 214 55.44 (51.80, 59.03) 205 53.11 (47.77, 58.37)
 Secondary 36 9.33 (6.57, 13.09) 63 16.32 (10.93, 23.67)
 College/university 21 5.44 (2.39, 11.91) 27 7.00 (4.30, 11.17)
Ethnic group
 Luo 344 88.43 (79.41, 93.81) 346 89.2 (80.69, 94.20)
 Luyha 28 7.2 (3.14, 15.64) 28 7.2 (3.11, 15.87)
 Kalenjin 7 1.8 (0.30, 9.93) 6 1.6 (0.37, 6.22)
 Kisii 6 1.5 (0.27, 8.19) 3 0.8 (0.31, 1.94)
 Other 4 1.0 (0.36, 2.91) 5 1.3 (0.46, 3.53)
Has 1+ child aged < 5 years 206 70.8 (61.84, 78.37) 201 72.8 (66.3, 78.50)
Has lost a child/child died 36 12.4 (10.70, 14.27) 29 10.5 (7.01, 15.45)
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multivariate model, only payment for a lab test was inde-
pendently associated with receipt of a dose of SP by DOT 
(AOR6.43, 95% CI 2.07,19.98).
Predictors of women receiving ISTp-DP
Predictors of women being screened with an RDT in 
the univariate analysis were: marital status, gravidity, 
education, SES, urban or rural location, consultation 
time, consultation duration, sick visit (reported by the 
woman), the presence of a resident microscopist at the 
facility, and delivery of prevention-of-mother-to-child-
(HIV) transmission (PMTCT) services (Table  8). In the 
final multivariate model, married women (AOR 0.77, 
95% CI0.47,1.26), and women living in rural areas (AOR 
0.78, 95% CI 0.02,0.27) were less likely to receive ISTp-
DP while women making a sick visit (AOR 1.78, 95% 
CI 1.31,2.41) and being tested in a health facility with a 
resident microscopist (AOR 3.75, 95% CI 1.31,2.40) were 
more likely to receive ISTp-DP.
Discussion
This is the first implementation feasibility study of a 
‘screen and treat’ strategy undertaken in sub-Saharan 
Africa despite several clinical trials to assess its potential 
as an alternative preventive strategy to IPTp-SP [13–16]. 
The study found that implementation as assessed through 
the systems effectiveness of ANC clinics to deliver ISTp-
DP according to guidelines in a routine setting was poor 
and highlights several challenges for integration in ANC. 
The study provided useful insights for countries in sub-
Saharan Africa that have introduced an adaptation of 
ISTp which uses screening at first ANC visit alongside 
IPTp as a ‘hybrid strategy’ [28] and for potential adop-
tion of ISTp with more sensitive RDTs. The delivery of 
IPTp-SP, the current policy in Kenya since 1999 [29], 
performed better but was nevertheless imperfect. These 
results for IPTp-SP are similar to previous observational 
studies measuring the systems effectiveness of ANC clin-
ics to deliver IPTp-SP through routine health systems in 
Kenya [30], with adherence to DOT in both the Kenya 
studies exceeding that observed in Mali [26]. Healthcare 
provider performance may be improved through targeted 
interventions combining training, supervision, and group 
problem solving [31], and would be most effective if done 
simultaneously with the introduction of any new inter-
vention to avoid the persistent challenges and pitfalls 
experienced with IPTp-SP.
The ISTp-DP strategy not only requires the delivery of 
more components than IPTp-SP, making it more complex 
and time consuming to deliver, it includes the adminis-
tration of ACT with a 3-day regimen that has so far only 
been recommended and used for treatment of clinical 
cases [32]. The use of ACT for the prevention of malaria 
in pregnancy is, therefore, a new drug indication, and this 
study was the first time that health providers will have 
used DP for IPTp under routine conditions and that ANC 
Table 4 Intermediate and cumulative systems effectiveness of delivery of IPTp-SP (any dose)
a Analysis limited to participants who were not given any antimalarial for treatment and/or antiretroviral and for whom information on drugs received was 
available at exit
b 6 missing
c 17 missing
d 2 missing
e 1 missing
IPTp-SP arm (N = 342)a N n Intermediate process effectiveness, 
% (95% CI)
Cumulative 
delivery 
effectiveness %
DOT
 1. 2nd or 3rd  trimesterb 342 336 100
 2. Given any  SPc 319 239 74.9 (54.8,88.0) 74.9
 3. Given dose of 3 tablets 239 237 100 74.9
 4. Took dose by DOT 237 179 75.5 (31.7,95.4) 56.5
With or without DOT
 1. Given any SP 319 239 74.9 (54.8,88.0) 74.9
 2. Given dose of 3  tabletsd 239 237 100 74.9
 3a. Took dose by DOT 237 179 75.5 (31.7,95.4) 56.5
 3b. SP not given by DOT 237 58 24.5 (4.6,68.3) 24.5
 4. Has SP on exit 58 2 3.4 (0.2,38.0) 3.4
 5. Knows how to take 3 tablets  SPe 2 1 100.0 (0,100) 3.4
 6. Composite endpoint 336 180 53.6
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nurses had administered an artemisinin-based combi-
nation within ANC clinics. The complexity and novelty 
of the ISTp-DP intervention was reflected in the lower 
cumulative effectiveness of women who tested positive 
compared to IPTp-SP and highlighted several practical 
issues that would need to be addressed if delivery of ISTp 
were to be integrated in ANC.
Integration of ISTp in ANC will require a substantial 
role change for ANC staff involving malaria testing, drug 
administration and counselling. The practice of nurses 
performing malaria RDTs within ANC clinics was a new 
practice, with pregnant women routinely referred to lab-
oratories to have malaria diagnosis performed by labora-
tory technicians. Nurses do, however, routinely perform 
HIV testing and counselling. While there were some 
obvious differences in the RDT proficiency between staff 
from ANC and the laboratory, this analysis revealed that 
ANC staff are capable of conducting RDTs comparatively 
well and consistently across ANC visits 1–4 + . An ear-
lier study in this region of Kenya [33] using microscopy 
showed a prevalence of 18% in pregnant women attend-
ing ANC in the second and third trimesters. RDTs are 
known to have lower sensitivity than microscopy in preg-
nant women which may explain the lower prevalence 
(11%) found in this study. Alternative possible explana-
tions are reducing trends in malaria transmission or pro-
vider proficiency with RDTs.
Key departures from the study SOP among ANC staff, 
such as not wearing gloves, labelling the test with the cli-
ent’s name, or waiting for the full test time before read-
ing the result, may be an indication of time constraints 
within ANC. This would be consistent with the qualita-
tive findings where ANC nurses reported that delivering 
ISTp-DP increased their workload (Hoyt, pers. com-
mun.), however there was no association between receipt 
of ISTp-DP and client-to-staff ratio in the logistic regres-
sion analysis. The study did not provide gloves, and it is 
possible that gloves were not routinely provided to nurses 
working in ANC. Regarding labelling of RDT tests, the 
test result and drug (if test-positive) were given at the 
point of care such that nurses may not have perceived 
the need to label tests, in contrast to tests done on symp-
tomatic patients in the laboratory where treatment is 
prescribed by clinical staff located elsewhere in an outpa-
tient department. Indeed, the systems effectiveness anal-
ysis showed that a high proportion of women who tested 
positive were given DP during the ANC consultation. 
Regarding the test wait time, while the test result can 
appear earlier than the recommended wait time, training 
on use of RDTs should emphasise that adhering to wait 
times is critical to ensure accuracy. Integration of RDT 
tests in ANC may, therefore, be possible, however staff 
proficiency in using RDTs would need to be periodically 
reassessed to ensure quality as part of routine supervi-
sion. The views and perceptions of laboratory, pharmacy 
Table 5 Intermediate and cumulative systems effectiveness of delivery of ISTp-DP
a Analysis limited to participants who were not given any antiretroviral and who did not report having a fever
b 27 missing
c DP dose based on weight, stat dose given by DOT and remaining two doses given to take home—24 to 35.9 kg, 2 tablets; 36 to 74.9 kg, 3 tablets; > 75 kg, 4 tablets
IST arm (N = 360)a N n Intermediate process 
effectiveness, % (95% CI)
Cumulative delivery 
effectiveness, %
1. 2nd or 3rd trimester 
women
347 347 100 100
2. Given an RDT  testb 320 289 90.3 (70.7, 97.3) 90.3
3a. RDT negative 289 257 88.9 (84.3, 92.3) 90.3
3b. RDT −ve not given any 
drug
211 211 100 90.3 (3b = tested − ve)
4a. RDT +ve 289 32 11.1 (7.7, 15.7) 90.3
4b. RDT+ ve given any DP 32 29 90.6 (59.8, 98.4) 81.8
5. DP given at correct  dosec 29 25 86.2 (56.5, 96.8) 70.5
6. Given stat dose by DOT 25 11 44.0 (15.0, 77.7) 31.0
7. Correct no. tablets taken 11 11 100 31.0
8. Health worker describe 
to woman how to take 
remaining doses
11 2 0 5.6
9. Woman able to repeat 
instructions
2 0 0 (9 = tested+ ve)
10. Composite endpoint 347 211 60.8
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and nursing staff on these role changes are explored in-
depth in the qualitative study which showed that nurses 
were generally enthusiastic about taking on these roles, 
whereas laboratory and pharmacy staff voiced concerns 
over nurses performing testing and drug administration, 
respectively.
Table 6 RDT proficiency among laboratory and ANC staff in health facilities in the ISTp-DP arm
a Includes 6 missing trimester
Intermediate process Lab ANC
n Intermediate 
process 
effectiveness
Cumulative 
delivery effective-
ness
n Intermediate 
process effective-
ness ± 
Cumulative 
delivery effective-
ness ≠ 
Difference 
(Intermed-iate 
processes), %
% (95% CI) % % (95% CI) %
RDT performed
 1. 2nd and 3rd  trimestera 289 90.3 (70.7, 97.3) 90.3 289 90.3 (70.7, 97.3) 90.3 0
  2. RDT performed ANC 
or lab
15 5.2 (0.6, 34.7) 90.3 274 94.8 (65.3, 99.4) 90.3 0
 3. Gloves worn 11 73.3 (34.9, 93.4) 66.2 129 47.1 (13.8, 83.2) 42.5 -26.2
 4. RDT opened in front 
woman
11 100 66.2 126 97.7 (78.1, 99.8) 41.5 -2.3
 5. Fourth finger selected 4 36.4 (1.5, 95.6) 24.1 82 65.1 (51.1, 76.9) 27  + 28.7
 6a. Finger cleaned with 
alcohol
4 100 24.1 79 96.3 (76.4, 99.5) 26 -3.7
 6b. Without step 5 11 100 66.2 117 92.9 (76.9, 98.1) 40 -7.1
 7. RDT labelled patient’s name 10 90.9 (0.0, 100.0) 60.2 26 22.2 (10.5, 41.1) 8.9 -68.7
 8a. Correct volume/ml blood 
added
10 100 60.2 26 100 8.9 0
 8b. Without step 7 11 100 66.2 117 100 40 0
 9. Blood added to correct 
place
11 100 66.2 117 100 40 0
 10. Buffer added after blood 11 100 66.2 117 100 40 0
 11. Buffer added correct place 11 100 66.2 117 100 40 0
 12. > 20 < 35 min waiting time 6 54.5 (0.7, 99.5) 36.1 35 29.9 (13.7, 53.4) 12 − 24.6
 13. Control line visible 6 100 36.1 35 100 12 0
 14. RDT result read accurately 6 100 36.1 35 100 12 0
 15. Result given to women 6 100 36.1 35 100 12 0
16. Guidelines used 0 0 0 4 11.4 (0.3, 83.4) 1.4 + 11.4
Table 7 Predictors of systems effectiveness—IPTp-SP by DOT
Determinant n % OR 95% CI P value AOR 95% CI P value
Marital status 0.07 0.07
 Single 36 63.2 1 1
 Married 139 51.3 0.61 0.24, 1.54 0.28 0.10, 0.81
 Divorced/widowed 4 28.6 0.23 0.08, 0.65 0.55 0.01, 42.23
Sick visit 0.103
 No 143 54.6 1
 Yes 36 45.0 1.47 0.89, 2.41
Payment for lab test 0.05 0.01
 No 23 76.7 1 1
 Yes 5 38.5 5.26 1.02, 27.13 6.43 2.07, 19.98
Drugs given in pharmacy 0.01
 No 176 58.09 1
 Yes 3 18.75 6.0 1.87, 19.29
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With regards to integration of the administration of 
DP, even though over two thirds of women were given 
the correct dose according to weight by nursing staff, less 
than half these women were given the first dose by DOT 
of whom less than a fifth comprehended the instruc-
tions on how to take the remaining doses at home. The 
analysis shows that the requirement to give IPTp and the 
first dose of ISTp by DOT has a high impact on systems 
effectiveness. Data on adherence to SP given to pregnant 
women to take at home is sparse placing even greater 
emphasis on the importance of assuring health provider 
adherence to DOT for IPTp-SP. Findings from the paired 
qualitative study suggest that women often refuse to take 
SP by DOT on an empty stomach for fear of side effects 
such as nausea (Hoyt, pers. commun.) and other stud-
ies have shown that health providers may potentiate this 
reaction by first asking women whether they have eaten 
before giving IPTp-SP by DOT [34, 35].
Adherence to DP when used for prevention in preg-
nancy was key concern voiced by health providers in the 
Table 8 Predictors of systems effectiveness—ISTp-DP
Determinant n % OR 95% CI P value AOR 95% CI P value
Gravidity 0.06
 Primigravidae 89 42.4 1
 Secundigravidae 80 37.7 0.82 0.50, 1.35
 Multigravidae 120 33.8 0.69 0.50, 0.97
Marital status 0.01 0.009
 Single 53 42.1 1 1
 Married 234 37.2 0.82 0.49, 1.36 0.77 0.47, 1.26
 Divorced/widowed 2 9.1 0.14 0.04, 0.46 0.13 0.04, 0.43
Education  levela 0.1
 Primary 155 37.0 1
 Secondary 49 49.5 1.67 1.06, 2.62
 College/university 19 39.6 1.11 0.52, 2.38
 None/nursery 65 31.6 0.78 0.48, 1.28
SES 0.1
 1 most poor 43 26.5 1
 2 56 37.1 1.63 0.82, 3.23
 3 53 34.2 1.44 0.83, 2.49
 4 72 46.8 2.43 1.25, 4.72
 5 least poor 65 41.9 2.0 0.62, 6.42
Urban/rural  < 0.00019 0.0009
 Urban 56 83.6 1 1
 Rural 233 32.8 0.096 0.03, 0.30 0.78 0.02, 0.27
Consultation time 0.08
 a.m 76 1
 p.m 100 1.70 0.93, 3.12
Consultation duration 0.026
 < 1.5 h 173 1
 > 1.5 h 6 0.23 0.11, 0.84
Sick visit 0.0007 0.0015
  Yes 47 29.0 1 1
 No 242 39.4 1.59 1.28, 1.97 1.78 1.31, 2.41
Resident microscopist 0.07 0.05
 Yes 250 35.1 1 1
 No 39 60.9 2.90 0.89, 9.43 3.75 1.31, 2.40
PMTCT services given 0.13
 Yes 1 4.2 1
 No 242 36.67 13.31 1.21, 146.20
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acceptability study, highlighting that information about 
the timing of doses must be easy for women to com-
prehend, with emphasis on the importance of complet-
ing the full course [19]. There is a weak evidence base on 
adherence to multi-day ACT regimens for treatment of 
malaria in other populations [36], and apparently no evi-
dence on adherence in pregnant women.
The qualitative component of the feasibility study and 
also the acceptability study conducted in the trial setting 
found that the delivery of ISTp-DP by ANC nurses was 
viewed positively by most health providers as it reduces 
wait times for women and improves continuity of care 
[19]. The qualitative study found the main implementa-
tion challenges for ISTp-DP reported by laboratory staff 
was the perceived lack of RDT sensitivity in comparison 
to microscopy, which they thought may leave women 
unprotected and, therefore, vulnerable to malaria, a con-
cern not shared by ANC nurses [19]. Indeed, the clinical 
trial comparing ISTp-DP and IPTp-DP versus IPTp-SP 
showed ISTp-DP to be inferior to IPTp-SP in this area of 
high SP resistance and high malaria transmission [15]. 
The authors of this and the other ISTp trials concluded 
that at the current levels of RDT sensitivity [13, 14, 16], 
ISTp with RDTs for testing is not a suitable alternative to 
IPTp-SP in areas of high SP resistance.
In an attempt to bolster malaria in pregnancy preven-
tion strategies some countries in sub-Saharan Africa 
with high levels of SP resistance have already adopted an 
adaptation of ISTp by combining single test and treat-
ment at first ANC visit as a ‘hybrid strategy’ with IPTp-
SP, using RDTs in ANC in Tanzania [37] and microscopy 
or RDT in Kenya (Kariuki, pers. commun.). Since adopt-
ing this hybrid strategy, the uptake of routine testing as 
an ANC-based intervention in Tanzania has increased 
substantially from 36.7% in 2014 to 88.8% in 2017 [37]. 
Furthermore, recent modelling studies using trial data 
from Kenya and five other countries (Burkina Faso, The 
Gambia, Ghana, Mali and Malawi) have shown that a 
hybrid strategy may offer additional benefit especially in 
areas with high-grade SP resistance [38]. The authors of 
the modelling paper suggest that screening and treatment 
in the first trimester in areas where IPTp-SP is contrain-
dicated, for example in areas of very high SP resistance, 
could also substantially improve pregnancy outcomes, 
particularly if using highly sensitive RDTs.
This study highlights several practical issues that will 
need to be addressed if ISTp were to be integrated in 
ANC. These include, for example, formal role changes to 
enable nurses to take on test and treat strategies, changes 
to supply and management procedures for drugs and 
RDTs, training on RDT testing and drug administration 
and counselling, and expansion of supervision checks on 
nurses. Screening for malaria as part of integrated point-
of-care testing for malaria at ANC with other stand-
ard tests routinely provided to pregnant women such as 
HIV, syphilis, and malaria, has shown promise. A study 
in western Kenya by Young et al. [39] showed that inte-
grated testing led to a substantial increase in testing rates 
for syphilis, malaria, and anaemia, providing an opportu-
nity for improved management of all four conditions in 
the context of a well-established HIV rapid testing pro-
gramme in pregnancy. The study found that high staff 
turnover was a predictor of pregnant women not receiv-
ing a full antenatal screening profile at first visit, it did 
not however assess health provider proficiency of the 
four RDT tests. In a related qualitative study, high client 
to healthcare worker volume ratio, stock-outs and poor 
working conditions challenged the delivery of adequate 
counselling and management of the four conditions [40].
Limitations
The study had several limitations. While ANC client to 
staff ratio was a criterion for matching health facilities 
however the number of staff and ANC attendance rates 
changed between designing the study and undertaking 
the evaluation (18  months later). However,  the logistic 
regression analysis for predictors did not find an associa-
tion between receipt of IPTp or ISTp and either consulta-
tion duration or ANC staff  to client ratio, though there 
was an association between consultation duration and 
ISTp receipt in the univariate analysis. Efforts were made 
not to interfere with routine MOH health system prac-
tices, but some level of study oversight was required to 
ensure a constant supply of RDTs and study drugs. The 
unstructured observations used for identifying systems 
effectiveness may have been influenced by the Haw-
thorne effect, where participants who are being observed 
may change their usual behaviour or practices [41, 42]. 
In this case, it was assumed that any change in health 
provider behaviour was towards ‘best behaviour’ but the 
sample size/study duration was considered sufficient for 
any behaviour change to revert back to normal during the 
course of the study [40]. Also, interpretation of the find-
ings suggest that the Hawthorne effect was an unlikely 
factor given low systems effectiveness, particularly of 
ISTp-DP [43]. The process for enrolling pregnant women 
was based on feasibility and was not technically random, 
such that there may be a bias towards selection of women 
attending at certain times of day. Data on the timing of 
doses of IPTp-SP was obtained from ANC cards and the 
IPTp-SP analysis restricted to doses taken at least one 
month apart. Finally, stock availability on the day of the 
survey is assumed on the basis on the monitoring reports 
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from the study coordinator, and no stockouts were 
reported during the survey days.
Conclusion
The systems effectiveness of ANC clinics to deliver the 
ISTp-DP under routine conditions was poor as was the 
delivery of IPTp-SP, a far simpler strategy to deliver yet 
still presenting implementation challenges more than 
two decades after its introduction. The study highlights 
several practical issues that would be needed for integra-
tion of ISTp-DP and provides useful insights for countries 
in sub-Saharan Africa that have introduced the ‘hybrid 
strategy’ and for any future adoption of ISTp with more 
sensitive RDTs. RDT testing by ANC staff is feasible and 
simple proficiency testing may be used to identify areas 
that require strengthening. The administration of DP by 
ANC nurses however appears to present a challenge, par-
ticularly provision of the first dose by DOT and the qual-
ity of patient counselling. Evidence for pregnant women’s 
adherence to multi-day ACT regimens for either preven-
tion or treatment will be needed to assess overall effec-
tiveness of the ISTp strategy.
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